STXS

Stereotaxis, Inc. 2006 Annual Report (10-K) Summary

Business Context and Reporting Period

This report covers the fiscal year ended December 31, 2006. Stereotaxis, Inc. designs, manufactures, and markets the Stereotaxis System, an advanced cardiology instrument control system used in hospital catheterization labs ("cath labs"). The system utilizes computer-controlled magnetic fields to navigate catheters and guidewires for the treatment of arrhythmias and coronary artery disease. As of year-end, the company had sold and delivered 66 NIOBE systems and held approximately $45.3 million in outstanding purchase orders.

Key Financial Metrics

Revenue Breakdown: System sales were $22.7 million (up 78% from 2005), driven by the sale of 23 systems. Revenue from disposables, service, and accessories was $4.5 million (up 100%).

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 81% year-over-year, primarily due to a higher volume of system installations (23 in 2006 vs. 13 in 2005) and a 11% increase in average selling price.
• Expense Increases: Operating expenses rose to $61.0 million from $51.3 million.
  • Research & Development: Increased 22% to $21.8 million due to new projects and platform development.
  • Sales & Marketing: Increased 40% to $22.5 million due to hiring and expanded programs.
  • General & Administrative: Increased 15% to $16.6 million, partly due to the adoption of SFAS 123(R) for stock-based compensation.
• One-Time Items: The 2005 period included a $2.9 million royalty settlement expense related to a patent dispute with the University of Virginia, which did not recur in 2006.
• Liquidity: Cash and short-term investments surged from $10.7 million to $37.0 million, largely due to a February 2006 equity offering that raised approximately $61.7 million in net proceeds.

Outlook, Risks, and Management Commentary

Outlook: Management expects to incur substantial net losses in 2007 and 2008 as they scale sales and marketing and pursue regulatory approvals for new products. The company anticipates achieving break-even operating performance by the end of 2008.

Key Risks:

• Market Adoption: Success depends on hospitals purchasing expensive capital equipment and physicians adopting a new technology over established manual methods.
• Regulatory Dependence: Future revenue relies on FDA and international approvals for new disposable devices (e.g., HELIOS II ablation catheter).
• Collaboration Risks: The company relies heavily on strategic alliances with Siemens, Philips, and Biosense Webster for sales, distribution, and service. Failure of these partnerships could materially impact operations.
• Backlog Uncertainty: Approximately 25% of the $45.3 million backlog is expected to be filled beyond 2007, and orders are subject to cancellation or delay due to hospital construction cycles.

Investor Verification Checklist

• Backlog Conversion: Verify the rate at which the $45.3 million purchase order backlog converts to recognized revenue, noting the risk of cancellations.
• Regulatory Milestones: Monitor the status of the PMA application for the HELIOS II ablation catheter, expected approval in 2007.
• Partnership Health: Assess the stability and performance of alliances with Siemens, Philips, and Biosense Webster, which are critical for distribution and service.
• Cash Burn Rate: Review quarterly cash flow to ensure the $37 million cash balance is sufficient to fund operations through the projected 2008 break-even point.
• Reimbursement Policies: Confirm that third-party payors continue to reimburse procedures performed with the Stereotaxis System under existing billing codes.